Next Article in Journal
Preliminary Phytochemical Analysis and Evaluation of the Biological Activity of Leonotis nepetifolia (L.) R. Br Transformed Roots Extracts Obtained through Rhizobium rhizogenes-Mediated Transformation
Previous Article in Journal
Different Lipid Signature in Fibroblasts of Long-Chain Fatty Acid Oxidation Disorders
Previous Article in Special Issue
Radiologic Assessment of Osteosarcoma Lung Metastases: State of the Art and Recent Advances
Review

Targeting the VEGF Pathway in Osteosarcoma

1
Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut 166830, Lebanon
2
Department of Medical Oncology and INSERMU830, Curie Institute, 75005 Paris, France
3
Department of Hematology/Oncology, Presbyterian Healthcare Services, Albuquerque, NM 87110, USA
4
Department of Cancer Medicine, Gustave Roussy, 94800 Villejuif, France
5
Sarcoma Group, Gustave Roussy, 94800 Villejuif, France
6
Department of Medical Oncology and INSERM U1218, Institut Bergonié, 33000 Bordeaux, France
*
Author to whom correspondence should be addressed.
Academic Editor: Kyu Yun Jang
Cells 2021, 10(5), 1240; https://doi.org/10.3390/cells10051240
Received: 23 March 2021 / Revised: 7 May 2021 / Accepted: 9 May 2021 / Published: 18 May 2021
(This article belongs to the Special Issue Research Advances and Therapy of Human Osteosarcoma)
Osteosarcoma is the most common primary tumor of the bones affecting mainly young adults. Despite the advances in the field of systemic anticancer therapy, the prognosis of relapsed of metastatic osteosarcoma patients remain dismal with very short survival. However, the better understanding of the pathophysiology of this subtype of sarcoma has led to the identification of new targeted agents with significant activity. In fact, increased angiogenesis plays a major role in the tumor growth and survival of osteosarcoma patients. Several targeted agents have demonstrated a significant anti-tumor activity including multi-kinase inhibitors. In this review, we will discuss the pathophysiology, rationale, and role of targeting angiogenesis via the VEGF pathway in patients with osteosarcoma with emphasis on the published clinical trials and future directions. View Full-Text
Keywords: osteosarcoma; vascular endothelial growth factor A; protein kinase inhibitors; angiogenesis; sarcoma; bone neoplasms osteosarcoma; vascular endothelial growth factor A; protein kinase inhibitors; angiogenesis; sarcoma; bone neoplasms
Show Figures

Figure 1

MDPI and ACS Style

Assi, T.; Watson, S.; Samra, B.; Rassy, E.; Le Cesne, A.; Italiano, A.; Mir, O. Targeting the VEGF Pathway in Osteosarcoma. Cells 2021, 10, 1240. https://doi.org/10.3390/cells10051240

AMA Style

Assi T, Watson S, Samra B, Rassy E, Le Cesne A, Italiano A, Mir O. Targeting the VEGF Pathway in Osteosarcoma. Cells. 2021; 10(5):1240. https://doi.org/10.3390/cells10051240

Chicago/Turabian Style

Assi, Tarek, Sarah Watson, Bachar Samra, Elie Rassy, Axel Le Cesne, Antoine Italiano, and Olivier Mir. 2021. "Targeting the VEGF Pathway in Osteosarcoma" Cells 10, no. 5: 1240. https://doi.org/10.3390/cells10051240

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop